+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Orphan Drug"

From
From
Acute Radiation Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Acute Radiation Syndrome - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
Transforming growth factor beta inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Transforming growth factor beta inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 150 Pages
  • Global
From
Amyloid precursor protein secretase inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Amyloid precursor protein secretase inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Danicopan Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Danicopan Emerging Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
Gene Therapy For Ocular Rare Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Gene Therapy For Ocular Rare Disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
From
Global Fabry Disease Drugs Market 2024-2028 - Product Thumbnail Image

Global Fabry Disease Drugs Market 2024-2028

  • Report
  • January 2024
  • 149 Pages
  • Global
From
From
From
2021 Pharmaceuticals Research Review - Product Thumbnail Image

2021 Pharmaceuticals Research Review

  • Report
  • March 2022
  • 299 Pages
  • Global
From
From
ROI in Pharmaceutical R&D: How to Halt the Decline - Product Thumbnail Image

ROI in Pharmaceutical R&D: How to Halt the Decline

  • Report
  • December 2019
  • 196 Pages
  • Global
From
Loading Indicator

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them. The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives. Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more